Orogen's Discovery Pipeline

Orogen Therapeutics' mission is to deliver groundbreaking clinical solutions to patients with serious unmet medical needs.

The company is revolutionizing small-molecule drug discovery through its proprietary platform that integrates DNA-encoded libraries (DEL) with massive chemical diversity of billions of compounds, virtual screening and AI-driven computation.

This unique foundation enables the efficient derivation of novel drug candidates against a broad range of target classes.

We apply our DEL-enabled platform into discrete target, therapeutic area and clinical indication verticals, the first of which is developing small molecule alternatives to biological products in the immuno-inflammation (INI) space.

Medically and commercially successful biologics developed for cytokine targets have validated the value of this space in multiple therapeutic areas including dermatology, rheumatology and gastroenterology for indications like psoriasis, eczema, psoriatic arthritis, rheumatoid arthritis, Crohn's disease and IBD.

Oral small molecule medicines with good safety and efficacy profiles represent attractive alternatives to biologics for many reasons.

Enter Orogen's first focus area: small molecule alternatives to biologics, with multiple hit series identified against a range of cytokine targets, and several candidates in lead optimization aimed at near-term lead selection.